ArticleIrish journal of medical science2026
Association of CXCR7 and CXCR4 expression with tumor immune phenotypes in tubo-ovarian high-grade serous carcinoma.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor-infiltrating lymphocytes (TILs) are associated with favorable outcomes in high-grade serous ovarian carcinoma (HGSC); however, the tumor microenvironment may modulate immune cell infiltration. This study aimed to evaluate the association between tumor and stromal expression of CXCL12, tumor expression of CXCR4 and CXCR7, immune phenotypes, and survival outcomes in tubo-ovarian HGSC.
methodsEighty-six patients with primary tubo-ovarian HGSC who underwent cytoreductive surgery were retrospectively analyzed. Immunohistochemical expression of CXCL12 (tumor and stroma), CXCR4, and CXCR7 was assessed. TILs were semi-quantitatively scored and dichotomized as low (score 1) or high (scores 2-3). Immune phenotypes were classified as immunogenic, immune-excluded, or immune-ignorant. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using Kaplan-Meier methods, log-rank tests, and Cox regression. Multivariable logistic regression was used to identify factors associated with high TILs.
resultsMedian RFS was 23.2 months (95% CI, 19.2-27.1) and median OS was 47.3 months (95% CI, 36.3-55.0). RFS differed significantly across immune phenotypes (log-rank p=0.047), with shorter RFS observed in the immune-excluded phenotype compared with the immunogenic phenotype (hazard ratio, 2.20; 95% CI, 1.14-4.25). High tumor CXCR7 expression was independently associated with a lower likelihood of high TILs (adjusted odds ratio, 0.22; 95% CI, 0.07-0.65). CXCL12 expression was not associated with survival outcomes.
conclusionTumor CXCR7 expression is associated with reduced lymphocytic infiltration and an immune-excluded phenotype in HGSC, suggesting a potential role of the CXCR7 axis in shaping the tumor immune microenvironment.
Indexed as
Identifiers
42126757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.